📊 LCTX Key Takeaways
Is Lineage Cell Therapeutics, Inc. (LCTX) a Good Investment?
Lineage Cell Therapeutics exhibits severe operational distress with negative free cash flow of $19.4M annually and essentially flat revenue ($14.6M, 0% YoY growth), indicating failed commercialization despite substantial R&D spending. While the company maintains adequate short-term liquidity ($40.8M cash) and zero debt, current burn rate implies 2-year runway and likely dilutive capital raises ahead; sustainable recovery requires dramatic revenue acceleration.
Fundamentals show persistent losses and flat revenue, with extremely negative operating and net margins indicating limited commercial traction. Liquidity is solid with substantial cash, high current ratio, and no debt, providing near-term runway. Without clear revenue acceleration or expense discipline, cash burn remains a key headwind.
Why Buy Lineage Cell Therapeutics, Inc. Stock? LCTX Key Strengths
- Strong liquidity position with 5.20x current ratio and $40.8M cash reserves providing near-term survival cushion
- Clean balance sheet with zero debt and no interest burden, eliminating financial distress risk in near term
- Healthy 56.8% gross margin demonstrates potential for profitability if revenue base scales significantly
- Strong liquidity and 5.2x current ratio
- Zero long-term debt and no interest burden
- Positive gross margin indicating potentially scalable unit economics
LCTX Stock Risks: Lineage Cell Therapeutics, Inc. Investment Risks
- Severe negative free cash flow of $19.4M annually with approximately 2 years runway before capital depletion at current burn rate
- Revenue completely stagnant at 0% YoY growth despite massive operating losses, indicating fundamental product commercialization failure
- Operating margin of -251.6% and net margin of -436.5% indicate operating expenses 3.5x+ revenue with no clear path to breakeven
- Dilutive capital raises highly likely, requiring equity financing to avoid insolvency
- Sustained large operating and net losses
- Flat revenue growth suggests weak commercialization
- Negative free cash flow may require future capital raises/dilution
Key Metrics to Watch
- Quarterly revenue growth rate and pipeline advancement to commercial products
- Operating cash burn rate trend and updated cash runway projections
- R&D spend efficiency improvements and clinical trial progress or regulatory approvals
- Operating cash flow (burn rate)
- Revenue growth (YoY)
Lineage Cell Therapeutics, Inc. (LCTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.20x current ratio provides a solid financial cushion.
LCTX Profit Margin, ROE & Profitability Analysis
LCTX vs Healthcare Sector: How Lineage Cell Therapeutics, Inc. Compares
How Lineage Cell Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lineage Cell Therapeutics, Inc. Stock Overvalued? LCTX Valuation Analysis 2026
Based on fundamental analysis, Lineage Cell Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lineage Cell Therapeutics, Inc. Balance Sheet: LCTX Debt, Cash & Liquidity
LCTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lineage Cell Therapeutics, Inc.'s revenue has grown significantly by 235% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.09 indicates the company is currently unprofitable.
LCTX Revenue Growth, EPS Growth & YoY Performance
LCTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.7M | -$3.0M | $-0.02 |
| Q2 2025 | $1.4M | -$5.8M | $-0.03 |
| Q1 2025 | $1.4M | -$4.1M | $-0.02 |
| Q3 2024 | $1.2M | -$3.0M | $-0.02 |
| Q2 2024 | $1.4M | -$5.2M | $-0.03 |
| Q1 2024 | $1.4M | -$4.4M | $-0.03 |
| Q3 2023 | $1.2M | -$6.1M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lineage Cell Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
LCTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lineage Cell Therapeutics, Inc. (CIK: 0000876343)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LCTX
What is the AI rating for LCTX?
Lineage Cell Therapeutics, Inc. (LCTX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LCTX's key strengths?
Claude: Strong liquidity position with 5.20x current ratio and $40.8M cash reserves providing near-term survival cushion. Clean balance sheet with zero debt and no interest burden, eliminating financial distress risk in near term. ChatGPT: Strong liquidity and 5.2x current ratio. Zero long-term debt and no interest burden.
What are the risks of investing in LCTX?
Claude: Severe negative free cash flow of $19.4M annually with approximately 2 years runway before capital depletion at current burn rate. Revenue completely stagnant at 0% YoY growth despite massive operating losses, indicating fundamental product commercialization failure. ChatGPT: Sustained large operating and net losses. Flat revenue growth suggests weak commercialization.
What is LCTX's revenue and growth?
Lineage Cell Therapeutics, Inc. reported revenue of $14.6M.
Does LCTX pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
Where can I find LCTX SEC filings?
Official SEC filings for Lineage Cell Therapeutics, Inc. (CIK: 0000876343) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LCTX's EPS?
Lineage Cell Therapeutics, Inc. has a diluted EPS of $-0.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LCTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lineage Cell Therapeutics, Inc. has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LCTX stock overvalued or undervalued?
Valuation metrics for LCTX: ROE of -142.6% (sector avg: 15%), net margin of -436.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LCTX stock in 2026?
Our dual AI analysis gives Lineage Cell Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LCTX's free cash flow?
Lineage Cell Therapeutics, Inc.'s operating cash flow is $-18.9M, with capital expenditures of $522.0K. FCF margin is -133.6%.
How does LCTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -436.5% (avg: 12%), ROE -142.6% (avg: 15%), current ratio 5.20 (avg: 2).